3:11 PM
 | 
Jan 29, 2018
 |  BC Extra  |  Company News

Sanofi to acquire Ablynx in €3.9B deal

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire Nanobodies company Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) for €45 per share in cash, or about €3.9 billion ($4.84 billion). The price is a 21% premium to Ablynx's close of €37.12 on Friday, before the deal was announced, and a 48% premium to the €30.50 per share offered by Novo Nordisk A/S (CSE:NOVOB;...

Read the full 267 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >